Clinical Implications of Co‐administering Apixaban with Key Interacting Medications

With many available data sources, clinicians need to consider the benefit‐risk profile of individual anticoagulants when balancing the need for anticoagulation, including evaluating the risks in patients with comorbidities and potential drug‐drug interactions. This narrative review presents clinical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology in drug development 2024-09, Vol.13 (9), p.961-973
Hauptverfasser:	Favatella, Nicholas, Dalton, David, Byon, Wonkyung, Merali, Samira J., Klem, Christian
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - pharmacokinetics anticoagulation apixaban atrial fibrillation benefit‐risk cancer‐associated thrombosis Clinical Trials, Phase III as Topic COVID-19 Drug Treatment - methods COVID‐19 Drug Interactions Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - pharmacokinetics Humans Neoplasms - drug therapy Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - pharmacokinetics Pyridones - administration & dosage Pyridones - adverse effects Pyridones - pharmacokinetics Risk Assessment Thromboembolism - drug therapy Thromboembolism - etiology venous thromboembolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!